OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Hussain on the Safety Profile of Olaparib in the PROfound Trial in mCRPC

September 22nd 2020

Maha Hussain, MD, FACP, FASCO, discusses the safety profile of olaparib as observed in the phase 3 PROfound trial in men with metastatic castration-resistant prostate cancer.

Dr. Trinh on Re-Establishing Standard Surgical Procedures in Prostate Cancer

September 22nd 2020

Quoc-Dien Trinh, MD, discusses the challenges of re-establishing standard surgical procedures in patients with prostate cancer following the initial wave of the coronavirus disease 2019 pandemic.

Dr. Nowakowski on the Rationale of the ENGINE Trial in DLBCL

September 22nd 2020

Grzegorz S. Nowakowski, MD, discusses the rationale for the ongoing, randomized phase 3 ENGINE study in diffuse large B-cell lymphoma.

Dr. Hill on the SADAL Trial With Selinexor in DLBCL

September 22nd 2020

Brian T. Hill, MD, PhD, discusses the data from the SADAL trial that led to the FDA approval of selinexor for use in patients with diffuse large B-cell lymphoma.

Dr. Maddocks on Remaining Challenges in Follicular Lymphoma

September 22nd 2020

Kami J. Maddocks, MD, discusses remaining challenges in treating patients with follicular lymphoma.

Dr. Trinh on the Impact of the COVID-19 Pandemic on Prostate Cancer

September 21st 2020

Quoc-Dien Trinh, MD, discusses the impact of the coronavirus disease 2019 pandemic on prostate cancer.

Dr. Choudhury on the Different States of Nonmetastatic CRPC

September 21st 2020

Atish D. Choudhury, MD, PhD, discusses the different states of nonmetastatic castration-resistant prostate cancer.

Dr. Nguyen on Future Research in High-Risk Prostate Cancer

September 21st 2020

Paul L. Nguyen, MD, discusses future research in high-risk prostate cancer.

Dr. Zalcberg on Updated Results from the Phase 3 INVICTUS Study in Advanced GIST

September 20th 2020

John Zalcberg, PhD, OAM, discusses updated results from the phase 3 INVICTUS trial in advanced gastrointestinal stromal tumor.

Dr. Skarbnik on the Importance of Personalized Treatment for Follicular Lymphoma

September 19th 2020

Alan P. Z. Skarbnik, MD, discusses the importance of personalizing treatment for patients with follicular lymphoma.

Dr. Pothuri on Patient-Reported Outcomes With Niraparib in Advanced Ovarian Cancer

September 18th 2020

Bhavana Pothuri, MD, discusses patient-reported outcomes with niraparib in advanced ovarian cancer.

Dr. Stratigos the Rationale to Evaluate Cemiplimab in Locally Advanced BCC

September 18th 2020

Alexander J. Stratigos, MD, discusses the rationale to evaluate cemiplimab-rwlc in locally advanced basal cell carcinoma.

Dr. Batlevi on Challenges Faced in Follicular Lymphoma Management

September 18th 2020

Connie L. Batlevi, MD, PhD, discusses challenges faced in the treatment of patients with follicular lymphoma.

Dr. Balzarotti on the Challenges of Treating Elderly DLBCL

September 18th 2020

Monica Balzarotti, MD, discusses the challenges of treating elderly patients with diffuse large B-cell lymphoma.

Dr. Visco on Next Steps for the MANTLE-FIRST Trial in Relapsed/Refractory MCL

September 17th 2020

Carlo Visco, MD, discusses the next steps for the international, retrospective MANTLE-FIRST trial in patients with relapsed/refractory mantle cell lymphoma.

Dr. Bose on Novel Agents Under Investigation in Essential Thrombocythemia

September 17th 2020

Prithviraj Bose, MD, discusses novel agents under investigation in essential thrombocythemia.

Dr. Trinh on Prostate Cancer Treatment During the COVID-19 Crisis

September 17th 2020

Quoc-Dien Trinh, MD, discusses current strategies on the treatment of patients with high-risk prostate cancer during the COVID-19 crisis.

Dr. Deol on the Approval of Brexucabtagene Autoleucel in MCL

September 17th 2020

Abhinav Deol, MD, discusses the approval of brexucabtagene autoleucel (Tecartus) in mantle cell lymphoma.

Dr. Bachier on the Potential Benefits of Liso-Cel in DLBCL

September 17th 2020

Carlos R. Bachier, MD, discusses the investigational CAR T-cell therapy lisocabtagene maraleucel in diffuse large B-cell lymphoma.

Dr. Kahl on Remaining Challenges in Indolent Non-Hodgkin Lymphoma

September 17th 2020

Brad S. Kahl, MD, discusses remaining challenges in the indolent non-Hodgkin lymphoma treatment landscape.